Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial : The Lancet
Links shared publicly online about this topic.
- 11total visits
Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial : The Lancet
Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. By - Prof Ludwig Kappos MD, David Li MD, Peter A Calabresi MD, Paul O'Connor MD,...
View full resource at thelancet.com
Most Recently Shared on November 1, 2011 at 7:19 pm By:
ocrelizumab targets immune system B cells that R implicated in MS, reduces MS-related brain lesions & disease activity http://t.co/sicBWhzd
Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial : The Lancet
thelancet.com — “Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. By - Prof Ludwig Kappos MD, David Li MD, Peter A Calabresi MD, Paul O'Connor MD,...” View full resource at thelancet.com
Most Recently Shared on November 1, 2011 at 12:24 pm By:
Study shows ocrelizumab successfully targets immune system B cells that are implicated in multiple sclerosis http://t.co/Qn6mgzYS #Neurology
Advertisement
